Arax Advisory Partners’s Repare Therapeutics RPTX Stock Holding History

Arax Advisory Partners’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,500	Closed	-$22K	–	4460
2025 Q3	$22K	Buy	12,500 +7,500	+150%	+$12K	﹤0.01%	2221
2025 Q2	$6.95K	Hold	5,000	–	–	﹤0.01%	2119
2025 Q1	$4.93K	Hold	5,000	–	–	﹤0.01%	1782
2024 Q4	$6.55K	Hold	5,000	–	–	﹤0.01%	1644
2024 Q3	$17.2K	Hold	5,000	–	–	﹤0.01%	1150
2024 Q2	$16.5K	Sell	5,000 -5,000	-50%	-$17.8K	﹤0.01%	1042
2024 Q1	$47.1K	Hold	10,000	–	–	0.01%	515
2023 Q4	$73K	Buy	10,000 +5,000	+100%	+$28K	0.01%	420
2023 Q3	$60.4K	Hold	5,000	–	–	0.01%	426
2023 Q2	$52.9K	Hold	5,000	–	–	0.01%	458
2023 Q1	$49.2K	Buy	+5,000	New	+$57.4K	0.01%	467

Other funds holding RPTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Arax Advisory Partners's RPTX Position: Q4 2025 in Review

Arax Advisory Partners sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 12,500 shares — an estimated $22K sold.

Arax Advisory Partners first reported a position in RPTX in Q1 2023 and held it in 11 quarters. The position peaked at $73K in Q4 2023. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

Arax Advisory Partners reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
Arax Advisory Partners sold 12,500 Repare Therapeutics shares in Q4 2025, an estimated $22K.
Arax Advisory Partners first reported a position in Repare Therapeutics in Q1 2023 and held it in 11 quarters.
Arax Advisory Partners's Repare Therapeutics position peaked at $73K in Q4 2023.
46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.